Regorafenib (Stivarga®) for GIST

Assessment Status Rapid Review Complete
Drug Regorafenib
Brand Stivarga®
Indication For the treatment of patients with gastrointestinal stromal tumours (GIST) who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI’s.
Assessment Process
Rapid review commissioned 18/09/2014
Rapid review completed 06/10/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended